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abstract
PURPOSE The aim of glioblastoma surgery is to maximize the extent of resection while preserving functional
integrity, which depends on the location within the brain. A standard to compare these decisions is lacking. We
present a volumetric voxel-wise method for direct comparison between two multidisciplinary teams of glio-
blastoma surgery decisions throughout the brain.
METHODS Adults undergoing ﬁrst-time glioblastoma surgery from 2012 to 2013 performed by two neuro-
oncologic teams were included. Patients had had a diagnostic biopsy or resection. Preoperative tumors and
postoperative residues were segmented on magnetic resonance imaging in three dimensions and registered to
standard brain space. Voxel-wise probability maps of tumor location, biopsy, and resection were constructed for
each team to compare patient referral bias, indication variation, and treatment variation. To evaluate the quality
of care, subgroups of differentially resected brain regions were analyzed for survival and functional outcome.
RESULTS One team included 101 patients, and the other included 174; 91 tumors were biopsied, and 181 were
resected. Patient characteristics were largely comparable between teams. Distributions of tumor locations were
dissimilar, suggesting referral bias. Distributions of biopsies were similar, suggesting absence of indication
variation. Differentially resected regions were identiﬁed in the anterior limb of the right internal capsule and the
right caudate nucleus, indicating treatment variation. Patients with (n = 12) and without (n = 6) surgical removal
in these regions had similar overall survival and similar permanent neurologic deﬁcits.
CONCLUSION Probability maps of tumor location, biopsy, and resection provide additional information that can
inform surgical decision making across multidisciplinary teams for patients with glioblastoma.
Clin Cancer Inform. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Standard treatment of glioblastoma consists of surgery
and radiotherapy with concomitant and adjuvant
chemotherapy. Nevertheless, the prognosis remains
dismal, with a 1-year survival rate of 39%.1 Initial
neuro-oncologic treatment decisions include whether
to undergo resective surgery or diagnostic biopsy or
refrain from surgery, if the patient is unﬁt or un-
motivated or the tumor is considered nonresectable.2,3
More extensive resections are associated with longer
survival in glioblastoma, often recognized as a causal
relation.4-7 The aim of neurosurgery is therefore to
maximize tumor removal while preserving functional
integrity. The surgical dilemma is that patient outcome
depends on the decision of where to stop tumor re-
moval. If stopped too early, more residual disease
remains, with the risk of earlier tumor recurrence and
shorter survival. If stopped too late, more tumor-
inﬁltrated functional brain is removed, leading to
brain function deﬁcits and reducing the patient’s
quality of life.8-11
Neurosurgical decision making depends on several
factors before surgery: the condition, age, and
comorbidity of the patient; neurologic signs and
symptoms; brain location of the tumor and derived
resectability; expectations of the neurosurgeon re-
garding beneﬁt and risk for the patient; and motivation
of the patient after discussion of these expectations.5,12-15
Intraoperatively, neurosurgeons use various tech-
niques to distinguish tumoral tissue from functional
brain tissue, such as image guidance with neuro-
navigation, magnetic resonance imaging (MRI), ul-
trasound or ﬂuorescence,16 and intraoperative
stimulation mapping.17 These factors and techniques
add up to practice variation in neuro-oncologic de-
cision making, which was captured by population-
based cohort studies evaluating patterns of care in
patients with glioblastoma.18-22 Biopsy percentages in
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these reports range widely: 5%,22 12%,20 24%,18 34%,19
and 44%.21 The quality of glioblastoma resection is usually
reported as the percentage of patients with a gross total
resection, which also ranges considerably: 28%,21 32%,18
46%,20 and 47%.22 Quality registries are being developed
to evaluate the quality of neuro-oncologic care23,24; how-
ever, no standards exist for the evaluation of neuro-
oncologic and neurosurgical decision making among
multidisciplinary teams. For comparison of teams, bias
resulting from heterogeneity of tumor locations within the
brain should be addressed; we proposed using a voxel-wise
approach in nonenhancing glioma.25
Voxel-wise methodologies were introduced for low-grade
gliomas to evaluate surgical decision making with volu-
metric analysis of preoperative tumor and residual disease
throughout the brain.26,27 The results of voxel-wise analyses
can be plotted in standard brain space, which is called
a probability map. Surgical decision making in non-
enhancing gliomas has been compared among neuro-
surgical teams using resection probability maps (RPMs).25
Ultimately, the best decision for a patient with glioblastoma
regarding biopsy or resection, and in case of resection, the
extent of tumor removal, should be based on a collaborative
body of objective data rather than on the intuition of one or
a few surgeons. A step in that direction is to compare and
discuss the patterns of current care. In this study, we
address the proof of concept for the use of probability maps
to assess and compare the patterns of (intra)operative
decision making between multidisciplinary teams in pa-
tients with glioblastoma.
METHODS
Patient Inclusion and Data Collection
Consecutive patients older than 17 years with a histo-
pathologic diagnosis of supratentorial glioblastoma and
ﬁrst-time brain surgery in 2012 or 2013 were included from
two brain tumor treatment centers: the Vrije Universiteit
Medical Center in Amsterdam and the University Medical
Center in Utrecht, the Netherlands. Patients underwent
either resection with glioblastoma removal or biopsy for
diagnosis. We deﬁned tumor removal for histopathologic
diagnosis only by an open or stereotactic approach as
biopsy and more contrast-enhanced tumor removal than
necessary for a histopathologic diagnosis by craniotomy as
resection. The histopathologic diagnosis was based on
WHO 2007 criteria. Written informed consent was obtained
from all patients.
The two multidisciplinary neuro-oncologic teams had
a similar approach to decision making in tumor board
meetings on surgical indications for new patients by con-
sensus of neurosurgeons based on patient and tumor
characteristics. Intraoperative decision making was per-
formed by neurosurgical teams under the supervision of
a neuro-oncologic surgeon from a pool of two or three per
center, respectively. Image guidance with neuronavigation
was routinely applied. Functional MRI, DTI tractography,
and intraoperative stimulation mapping for language and
motor functions were used by indication. The Utrecht team
had started using ﬂuorescence-guided microscopy in
2013; the Amsterdam team had not.
Baseline characteristics of these patients were extracted
from digital department databases, as well as from pre- and
postoperative MRI. MRI acquisition protocols were com-
parable between the two teams (Data Supplement). A
complication was deﬁned as a new intervention or intensive
care admission. A functional decline was deﬁned as a drop
in Karnofsky performance score of . 20 between admis-
sion and 6 weeks after surgery.
Brain Map Construction
The construction of brain maps is described in detail in the
Data Supplement. Brieﬂy, the enhancing portions of tumors
were segmented on pre- and postoperative T1-weighted
gadolinium-enhanced images. For patients who underwent
biopsy, postoperative MRI was usually omitted, and we
therefore considered the residual tumor to be identical to
the preoperative tumor. Next, tumor volumes were non-
linearly registered to the Montreal Neurological Institute
(MNI) 152 1-mm brain template to compare tumor loca-
tions between patients and teams.
Three types of probability maps were constructed by voxel-
wise aggregations of the registered tumor volumes, each
CONTEXT SUMMARY
Key objective:
To develop a method to compare patterns of surgical
decisions without bias from tumor location in patients
with glioblastoma across multidisciplinary teams.
Knowledge generated:
Probability maps of tumor location, biopsy and re-
section based on MRI before and after surgery en-
able comparison of patient selection and surgical
decisions across teams. We demonstrate referral bias
of patients with tumors in the left hemisphere and
differential tumor removal in the right caudate nu-
cleus between two teams.
Relevance:
Probability maps provide additional information that
can inform patient counseling and surgical decision-
making on biopsy or resection indications and on
optimization of stimulation mapping. Our ﬁndings
support the inclusion of standardized imaging in
neuro-oncological registries. Probability maps may
enhance knowledge transfer between neuro-
oncological teams and serve as educational
instrument.
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reﬂecting clinical decision making. First, a tumor probability
map (TPM) representing tumor burden before treatment was
constructed by summation of preoperative tumors divided by
the total number of patients treated by a team. A TPM dif-
ference between two teams would indicate referral or re-
cruitment bias given a tumor location. Second, a biopsy
probability map (BPM) representing the likelihood of a biopsy
procedure over resection was constructed for each team by
dividing the number of biopsies per location by the number of
resections. A BPM difference between two teams would in-
dicate treatment variation in indications for biopsy given
a tumor location. This can be considered a measure of
multidisciplinary neuro-oncologic team decision making.
Third, an RPM representing the likelihood of residual disease
after surgery was constructed. A difference between RPMs of
patients undergoing resection would indicate treatment var-
iation in tumor removal given an indication for resection. This
can be considered a measure of neurosurgical team decision
making during surgery. In addition, a difference between
RPMs based on all patients in a cohort, including those
undergoing biopsy or resection, would then indicate treatment
variation in tumor removal for all patients with newly diagnosed
glioblastoma. This can be considered an overall measure of
multidisciplinary neuro-oncologic decision making after ﬁrst-
time surgery for newly diagnosed glioblastoma.
Subgroup Analysis
As an example of quality evaluation from treatment varia-
tion, we determined the subgroup of patients involved in the
largest cluster of differentially resected voxels. Therefore,
we extracted clinical follow-up and radiologic data from
medical records to explore differences in outcome poten-
tially related to treatment variation.
RESULTS
Patient and Treatment Characteristics
A total of 279 patients were treated, 102 by the Amsterdam
team and 177 by the Utrecht team. For the probability map
analysis, 101 (99%) and 174 patients (98%) were available,
respectively. In two patients, the preoperative MR scan was
unavailable from the referring hospital, and in two patients, the
glioblastoma was nonenhancing. Patients were mostly com-
parable between teams in baseline characteristics (Table 1).
AnMR scan within 3 days after resection was obtained in 77
patients (100%) who underwent resection in Amsterdam
and in 68 (65%) of 104 in Utrecht. To adhere to current
imaging standards,28 we based the resection probabilities for
evaluation of neurosurgical decisions on the patients with
postoperative scans within 3 days. The quality of neuro-
surgical team decisions in patients undergoing resection was
not signiﬁcantly different between teams in terms of residual
volume, extent of resection, or outcome (Table 1).
Referral Bias
A signiﬁcant difference was indicated in relative tumor in-
cidence by the TPM comparison between both teams
(Fig 1). In several regions in the left hemisphere, regions with
differential tumor incidence were identiﬁed, such as the
caudate nucleus, anterior limb of the internal capsule, and
temporal stem. These observations seemed to be based on
systematic differences, such as referral or recruitment bias.
Variation in Biopsy Indications
No differentially biopsied regions were identiﬁed by the
BPM comparison between teams (Fig 2). The BPMs
TABLE 1. Baseline Patient and Treatment Characteristics and Outcomes
Characteristic
No. (%)
P
Amsterdam
Team
(n = 101)
Utrecht
Team
(n = 174)
Median age, years 63.2 66.1 .025
Female sex 37 (37) 68 (38) .798
Karnofsky performance score .160
100 9 (9) 5 (3)
90 22 (22) 54 (31)
80 23 (23) 40 (23)
70 28 (28) 34 (20)
60 12 (12) 19 (11)
50 7 (7) 12 (7)
40 0 3 (2)
30 0 1 (1)
Year of surgery .617
2012 49 (49) 77 (44)
2013 52 (52) 97 (56)
Tumor in left brain hemisphere 39 (39) 95 (55) .012
Median preoperative tumor volume, mL 28.7 37.9 .082
MRI timing
Days between preoperative MRI and
surgery
−4 −1 .000
Days between postoperative MRI and
surgery
1 3 .000
Surgical strategy .001
Biopsy 21 (21) 70 (40)
Resection 80 (79) 104 (60)
Median residual tumor volume, mL 1.0 0.3 .438
No. of patients undergoing resection with
residue , 3 mL
59 (74) 44 (42) .283
Median extent of resection, % 96.3 98.6 .206
No. of patients undergoing resection with
extent of resection . 95%
45 (56) 43 (41) .406
Outcomes
Median OS, months 12 9 .187
Complications 3 (3) 7 (4) .750
Functional decline 5 (5) 20 (11) .083
Abbreviations: MRI, magnetic resonance imaging; OS, overall survival.
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demonstrated that consensus existed regarding in which
brain regions biopsy was preferred over resection, such as
the thalamus, internal capsule, splenium of the corpus
callosum, and periventricular region around the occipital
horns, and conversely in which brain regions resection was
preferred over biopsy, such as the anterior temporal lobe,
right prefrontal cortex, and right inferior parietal lobe. The
absence of differences in the BPMs suggests that brain
location was not an important factor contributing to mul-
tidisciplinary decision making on performing a biopsy
procedure. Nevertheless, the overall biopsy percentage
differed, with 21 (21%) and 70 patients (40%) undergoing
biopsy in Amsterdam and Utrecht, respectively (P = .002).
Patients undergoing biopsy did not differ with regard to age
(median, 63.1 and 65.9 years), condition (Karnofsky
score , 70 in six [29%] and 16 [24%]), or tumor volume
(median, 27 and 29 mL), respectively.
Variation in Tumor Removal
Tumor removal between teams was comparable in many
brain regions. However, the Amsterdam team more often
resected tumor in the right caudate nucleus and anterior
limb of the right internal capsule than the Utrecht team
(Fig 3). Common regions where tumor was generally re-
moved included the temporal lobes, prefrontal cortices, and
superior parietal lobules. Other tumor-inﬁltrated regions were
commonly not removed, such as the anterior perforating
substance and corticospinal tract. The precision of these
probabilities varied by location depending on the number of
patients with information (Fig 1).
Subgroup Analysis of Patients With Different
Tumor Removal
The brain region with the largest differential resection prob-
ability was the right caudate nucleus and surrounding white
matter pathways, in which the Amsterdam team decided to
remove the tumor, whereas the Utrecht team did not. This
would probably have remained unnoticed without a proba-
bility map comparison. We identiﬁed 18 patients who un-
derwent resection. No differences were noted in neurologic
outcome, survival, postsurgical hydrocephalus, or ventricular
dissemination of glioblastoma for patients with (n = 12) and
without (n = 6) tumor removal (Data Supplement).
Variation in Oncologic Quality of Glioblastoma Surgery
The decisions for the whole cohort on whether to perform
biopsy or resection and the observed extents of resection
were similar between the two teams in both hemispheres
(Fig 4). Therefore, overall decisions on biopsy and extent of
resection do not depend on brain location.
DISCUSSION
The main ﬁnding of this study is that probability maps of
tumor location, biopsy, and resection enable the evaluation
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FIG 1. Tumor probability map (TPM) comparison of all 98 versus 174 patients per team to evaluate referral bias for the left (L; 38 v 95) and right (R)
hemispheres (60 v 79). Plotted from top to bottom are the TPMs from Amsterdam, TPMs from Utrecht, difference maps, and false discovery rate q value
maps. The color codes correspond with the adjacent legends. From left to right, the axial sections of theMontreal Neurological Institute (MNI) brain template
are shown of the plotted z coordinates. The Data Supplement provides results over all axial sections, including the unadjusted P value map.
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of surgical decision making among multidisciplinary teams
in patients with glioblastoma.
Its potential use is illustrated by some examples. First, we
identiﬁed a signiﬁcant difference in tumor lateralization
between two teams, and with TPM comparison, a more
detailed speciﬁcation of the brain regions involved could be
made. This bias could be related to regional referral pat-
terns of which we are as yet unaware. Because each center
is considered to serve designated geographic regions,
neurologists seldom cross-refer patients to other hospitals.
Second, we identiﬁed a signiﬁcant difference in biopsy
percentage between two teams. This could not be attrib-
uted to speciﬁc brain locations according to the BPM
analysis, nor to patient age, condition, or tumor volume.
The difference in ﬂuorescence guidance and application of
stimulation mapping is not an explanation, because these
techniques were used by the team performing more bi-
opsies and fewer extensive resections. It seems other
factors contributed to the differential overall biopsy pref-
erence, possibly related to expectations between the
multidisciplinary teams regarding the beneﬁts and risks of
resection.
In addition, several of the observed differences in neuro-
surgical decision making were related to unresolved clinical
dilemmas. Several plausible explanations were collected as
feedback from both neuro-oncologic teams for the difference
in resection probability lateral of the frontal horn at the level
of the caudate nucleus in the right hemisphere. As another
example of the potential use of the probability map com-
parison, our ﬁndings highlight these dilemmas. First, opin-
ions differed on the justiﬁcation of surgical removal of the
nondominant caudate nucleus. Arguments against removal
included the functional anatomy of the caudate nucleus,
which has been associated with behavior, sometimes
resulting in severe cognitive impairment, such as abulia, as
learned from observations in stroke29-32 and other focal le-
sions.33 In addition, the caudate nucleus is part of the
negative motor network, connected to the supplementary
motor area through the frontostriatal tract.34 For supra-
complete glioma resection, the caudate nucleus is consid-
ered a strict functional boundary by neurosurgeons who
push the limits of resection.35 In contrast, deﬁcits were
absent after caudate removal in low-grade glioma surgery.36
In our data, no argument was raised against removal of the
caudate to preserve the patient’s functional integrity, al-
though no systematic neuropsychological examinations were
available for these patients. Second, the opinions also dif-
fered on justiﬁcation of ventricular entry at the anterior horn
of the lateral ventricle between the two teams. One team
favored more extensive tumor removal, whereas the other
team primarily intended to avoid adverse events resulting
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FIG 2. Biopsy probability map comparison of all 98 versus 174 patients per team to evaluate multidisciplinary decision making on biopsy indications for the
left (L; 38 v 95) and right (R) hemispheres (60 v 79). A value of 0 represents a location where all patients have undergone resection, and a value of 1
represents a location where all patients have undergone biopsy. Note that the color code for biopsy probability in rows 1 and 2 is different from that in
Figure 1. The color codes for difference maps in row 3, and false discovery rates in row 4 are identical in all ﬁgures. The Data Supplement provides the full
results.
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from ventricular entry, such as hydrocephalus or tumor
seeding. Hydrocephalus is an uncommon complication after
glioma surgery, but it has been reported more frequently
after ventricular entry.37-42 Tumor seeding can be facilitated
by wide ventricular opening. Although early publications did
not ﬁnd support for this,43 later publications have indicated
more frequent leptomeningeal glioblastoma dissemination
after ventricular entry.38,44,45 In our data, tumor seeding only
occurred in cases with opening of the ventricle, although this
difference was not statistically signiﬁcant with this limited
number of patients. Altogether, our data do not support
avoidance of ventricular entry to prevent these complica-
tions. Third, the opinions differed on the use of intraoperative
stimulation mapping with cognitive tasks in the right frontal
lobe. One team argued that cognitive impairment is an
uncommon outcome and that cognitive mapping has not
been validated and could impede tumor removal. The other
team had started to develop a cognitive mapping protocol.
More recently, awake mapping of nonlanguage functions
has been proposed for low-grade glioma surgery, particu-
larly in the right hemisphere.46-51 On the basis of these
arguments and a small number of patients in our study, the
dilemma over removal of a tumor-inﬁltrated caudate nucleus
remains.
No standards exist for quality measurement of neuro-
oncologic care. Often, for a patient cohort, a variety of
outcome measures are reported. Examples of oncologic
outcome measures include the percentage of patients
undergoing biopsy, median extent of resection, percentage
of patients undergoing gross total resection, median re-
sidual disease volume, time to progression, and overall
survival time. Examples of functional outcome measures
include the percentage of patients with neurologic deﬁcits,
average cognitive performance scores, and health-related
quality-of-life indices. We postulate that in addition to these
outcomemeasures, probability map comparison of tumors,
biopsies, and resections aids in evaluating oncologic out-
come without bias from brain location. Probability maps
thus enable outcome comparison among hospitals treating
patients with diverging complexity of tumor locations. An-
other advantage is that probability map information is
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FIG 3. The resection probability map comparison of 77 versus 68 patients undergoing resection per team to evaluate neurosurgical decision making on
residual disease for the left (L; 28 v 32) and right (R) hemispheres (49 v 36). Note that the color code for resection probability in rows 1 and 2 is different from
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provides the full results.
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available early in the course of disease, so quality as-
sessment is not delayed until progression or survival. To
optimize decision making and improve quality of care,
a balance is required between oncologic and functional
goals.52 That is, quality evaluation should not be narrowed
to “less red is more quality” in BPMs and RPMs.
Several strengths of our study can be discerned. Volumetric
analysis of residual disease was an important innovation
comparedwith surgeon impression of resection completeness
for an individual patient; now probability map comparison
extends this by aggregating results for many patients per
multidisciplinary team. New patterns of disease and treatment
can be discovered, as demonstrated. By applying these
methods at high resolution, we avoid assumptions on elo-
quence and interpretation of brain region classiﬁcations.
Furthermore, an open-minded approach toward quality
evaluation, learning, and improvement by changing current
opinionswas required fromboth teams. Thewell-documented
patient cohorts were sizeable and seemed to represent clinical
practice, which encourages extrapolation of our results.
Limitations to our ﬁndings include technical and inclusion
issues. The technical observations on segmentation and
registration are described in detail in the Data Supplement.
Regarding inclusion, patients not undergoing surgery, and
consequently without histopathologic diagnosis, were not
included in our study. The impact of this potential selection
bias is small, because we identiﬁed only three patients in
Amsterdam with a radiologically presumed glioblastoma
without any surgery.
Our results have a number of practical implications. First,
BPMs and RPMs can identify patients who will beneﬁt most
from intraoperative stimulation mapping and guide intra-
operative stimulation mapping to the tumor regions with
most function variability to potentially improve decision
making. Instead of a static concept of functional and
nonfunctional brain territories (ie, brain eloquence14), we
now have a dynamic quantitative measurement per brain
voxel of resectability that applies to a patient cohort treated
by a team during a period of time. Second, neuro-oncologic
registries have been initiated for the collection of patient
data for quality evaluation.21,24,53 Our ﬁndings support the
inclusion of standardized imaging as part of this collection.
Third, our ﬁndings may serve patient counseling regarding
decision making for biopsy or resection indications within
multidisciplinary teams and for optimization of surgical
strategies within neurosurgical teams. Fourth, probability
maps may speed up knowledge transfer between neuro-
oncologic teams. Fifth, the use of probability maps may
enhance education and training of young neurologists,
neurosurgeons, and radiologists by putting treatment de-
cisions for individual patients into a broader perspective of
aggregated patient cohorts and by providing intuitive and
objective brain map visualization.
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FIG 4. The resection probability map comparison of all 98 versus 174 patients per team to evaluate multidisciplinary decisionmaking on tumor removal for the left
(L; 38 v 95) and right (R) hemispheres (60 v 79). The layout and color codes are identical to those in Figure 3. The Data Supplement provides the full results.
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Future work could focus on larger patient populations
to resolve the pictured clinical dilemmas and identify more
patterns of treatment variation. The impact on patient
outcome of identifying and resolving dilemmas resulting
from treatment variation remains to be determined. Fur-
thermore, RPMs could be used for individualized patient
care to predict resection results, contribute to image-
guided surgical plans, and evaluate resection results.
In conclusion, probability maps of tumor location, biopsy,
and resection provide additional information that can in-
form surgical decision making across multidisciplinary
teams for patients with glioblastoma.
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